San Diego, California--(Newsfile Corp. - March 11, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) (the Company), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced that it has entered into a securities purchase agreement for the sale of 4,000,000 shares of its common stock at $10.00 per share to certain investors in a private placement (the 'PIPE') to certain qualified institutional buyers.

加利福尼亚州圣地亚哥-（新闻文件公司-2024年3月11日）-Skye Bioscience，Inc.（OTCQB:Skye）（该公司），一家临床阶段的生物技术公司，专注于发现，开发和商业化新型治疗药物，调节内源性大麻素系统，今天宣布，该公司已签订证券购买协议，将其4000000股普通股以每股10.00美元的价格出售给某些投资者，以私募（“管道”）的形式出售给某些合格的机构买家。

Gross proceeds from the PIPE are expected to be $40 million before deducting any placement agent fees and offering-related expenses. The PIPE financing is expected to close on March 13, 2024, subject to the satisfaction of customary closing conditions.

在扣除任何配售代理费和发行相关费用之前，该管道的总收益预计为4000万美元。管道融资预计将于2024年3月13日关闭，但须满足常规关闭条件。

Investors in this financing included Perceptive Advisors, Velan Capital and Schonfeld Strategic Advisors, among others, and certain existing institutional Skye shareholders including a life science-focused investor, 5AM Ventures, Altium Capital and Sphera Healthcare.

此次融资的投资者包括Perceptive Advisors、Velan Capital和Schonfeld Strategic Advisors等，以及某些现有的Skye机构股东，包括专注于生命科学的投资者、5AM Ventures、Altium Capital和Sphera Healthcare。

Piper Sandler & Co. is acting as the lead placement agent and Oppenheimer & Co. is acting as a placement agent for the PIPE financing.

Piper Sandler&Co.担任首席配售代理，Oppenheimer&Co.担任管道融资的配售代理。

'Our January PIPE financing provided funding for our immediate Phase 2 clinical development plans for obesity and glaucoma. Adding additional capital gives us the ability to proactively expand the strategic development of our unique peripheral CB1 inhibitor, nimacimab, for obesity. This monoclonal antibody offers differentiated characteristics within this class of mechanism and we look forward to broadly assessing its therapeutic potential,' said Punit Dhillon, CEO and Chair of Skye.

“我们一月份的PIPE融资为我们针对肥胖和青光眼的第二阶段临床开发计划提供了资金。增加额外资本使我们能够积极扩大我们独特的外周CB1抑制剂尼莫昔单抗治疗肥胖症的战略发展。Skye首席执行官兼主席Punit Dhillon说，这种单克隆抗体在这类机制中提供了不同的特征，我们期待着广泛评估其治疗潜力。

'We are also pleased to add to our healthcare-focused institutional shareholder base.'

“我们也很高兴增加我们以医疗保健为重点的机构股东基础。”

The securities being issued and sold in the PIPE have not been registered under the Securities Act of 1933, as amended (the 'Securities Act'), or the securities laws of any state, and may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act.

管道中发行和出售的证券尚未根据1933年《证券法》（修订版）（“证券法”）或任何州的证券法进行登记，并且不得在美国发售或出售，除非根据有效的登记声明或证券法登记要求的适用豁免。

The Company has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock issued in this PIPE within 60 days of signing.

公司已同意在签署后60天内向证券交易委员会提交一份登记声明，登记在该管道中发行的普通股股份的转售情况。

About Skye Bioscience, Inc.

关于Skye Bioscience，Inc

Skye is focused on unlocking the pharmaceutical potential of the endocannabinoid system to treat diseases with metabolic, inflammatory, and fibrotic processes. Backed by leading life science venture investors, Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with significant clinical and commercial differentiation.

Skye专注于释放内源性大麻素系统的药物潜力，以治疗代谢，炎症和纤维化过程中的疾病。在领先的生命科学风险投资者的支持下，Skye的战略利用具有大量人类证据机制的生物靶标，开发具有显着临床和商业差异的一流疗法。

Nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1, showed a favorable safety and tolerability profile in a Phase 1 study. Skye plans to start a Phase 2 clinical trial in obesity comparing monotherapy and combination arms of nimacimab and a GLP-1R agonist in mid-2024. Enrollment has been completed for a Phase 2 clinical trial of SBI-100 Ophthalmic Emulsion, a CB1 agonist currently being studied in patients with glaucoma and ocular hypertension.

尼莫单抗是一种抑制外周CB1的负变构调节抗体，在1期研究中显示出良好的安全性和耐受性。Skye计划在2024年年中开始肥胖的2期临床试验，比较尼莫单抗和GLP-1R激动剂的单一疗法和联合疗法。SBI-100眼用乳剂的2期临床试验已经完成，目前正在青光眼和高眼压患者中研究CB1激动剂。

Topline data is expected in Q2 2024.

预计2024年第二季度将公布Topline数据。